Join the Seizures group to help and get support from people like you.
Seizures News (Page 4)
Related terms: Complex Partial Seizure, Fits, Convulsion, Absence Seizure
Fintepla (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)
Fintepla® has demonstrated efficacy in the most difficult-to-treat seizure types,1,2 including drop seizures, which cause a person to suddenly lose muscle tone, become limp, and fall to the ground, ...
FDA Approves Ztalmy (ganaxolone) for Seizures Associated with CDKL5 Deficiency Disorder
RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today...
FDA Medwatch Alert: Sagent Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Levetiracetam Injection, USP Due to Lack of Sterility Assurance
CHICAGO, IL – November 19, 2021 - Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of four lots of Levetiracetam Injection, USP, to the user level. The lack of container c...
UCB Announces Briviact (brivaracetam) Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older
ATLANTA, Aug. 30, 2021 /PRNewswire/ – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Briviact (brivaracetam) CV tablets, oral solution,...
Vimpat (lacosamide) Now Approved by FDA for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric Use for People Living with Epilepsy
ATLANTA, Nov. 17, 2020 /PRNewswire/ – UCB, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Vimpat (lacosamide) CV as adjunctive therapy...
FDA Approves Epidiolex (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex
CARLSBAD, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) – GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines,...
FDA Approves Valtoco (diazepam nasal spray) as a Seizure Rescue Treatment
SAN DIEGO, CA – January 13, 2020 – Neurelis, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Valtoco (diazepam nasal spray) as an acute treatment of intermittent, s...
FDA Approves Xcopri (cenobamate) for the Treatment of Partial-Onset Seizures in Adults
PANGYO, South Korea and PARAMUS, N.J., Nov. 21, 2019 /PRNewswire/ – SK Biopharmaceuticals, Co., Ltd., an innovative global pharmaceutical company focused on developing and bringing treatments to...
FDA Approves Nayzilam (midazolam) Nasal Spray to Treat Seizure Clusters
Brussels (Belgium) & Atlanta, Georgia (U.S.) – May 20 2019: UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application for the company’s newest ant...
FDA Approves Sympazan (clobazam) Oral Film for Adjunctive Treatment of Seizures Associated with Lennox-Gastaut Syndrome
WARREN, N.J., Nov. 2, 2018 /PRNewswire/ – Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved...
FDA Approves Fycompa for the Treatment of Partial-Onset Seizures in Pediatric Patients as Young as 4 Years Old
WOODCLIFF LAKE, N.J., Sept. 28, 2018 /PRNewswire/ – Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) expanded the indication of its antiepileptic drug Fycompa (perampanel)...
FDA Approves Diacomit (stiripentol) for Seizures Associated with Dravet Syndrome
On August 20, 2018, the U.S. Food and Drug Administration (FDA) approved Diacomit (stiripentol) for seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam. ...
FDA Approves Epidiolex (cannabidiol) to Treat Lennox-Gastaut Syndrome and Dravet Syndrome
June 25, 2018 – The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy,...
UCB Announces Briviact (brivaracetam) Now Approved by FDA to Treat Partial-Onset (Focal) Seizures in Pediatric Epilepsy Patients
Atlanta, Georgia (U.S.) & Brussels (Belgium), 0700 CEST, 14 May, 2018: UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for...
FDA Approves Afinitor Disperz (everolimus) for Tuberous Sclerosis Complex-Associated Partial-Onset Seizures
April 11, 2018 – On April 10, 2018, the Food and Drug Administration approved everolimus tablets for oral suspension (Afinitor Disperz, Novartis Pharmaceuticals Corp.) for the adjunctive treatment...
Further information
Related condition support groups
Seizure Prevention, Seizure Prophylaxis, Epilepsy
Related drug support groups
gabapentin, clonazepam, Valium, diazepam, Topamax, lamotrigine, pregabalin, Depakote, topiramate, view more... Keppra, progesterone, Trileptal, oxcarbazepine, levetiracetam, phenobarbital, Vimpat